{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:28Z","timestamp":1793608168949,"version":"4.5.0"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Eileen M. O\u2019Reilly, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, NY, whose research focuses on therapies for pancreas cancer, spoke with Cancer Discovery\u2019s Suzanne Rose about daraxonrasib combinations, treatment strategies under development, the need for genomic testing, and what big headlines might come in pancreas cancer.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nw2026-0092","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:19:11Z","timestamp":1790587151000},"page":"OF1-OF1","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Q&amp;A: Eileen O\u2019Reilly on Pancreatic Cancer"],"prefix":"10.1158","volume":"16","member":"1086","published-online":{"date-parts":[[2026,9,28]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NW2026-0092\/788583\/Q-amp-A-Eileen-O-Reilly-on-Pancreatic-CancerQ-amp","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/11\/OF1\/789565\/Q-amp-A-Eileen-O-Reilly-on-Pancreatic-CancerQ-amp","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/11\/OF1\/789565\/Q-amp-A-Eileen-O-Reilly-on-Pancreatic-CancerQ-amp","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:10:17Z","timestamp":1793607017000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/11\/OF1\/789565\/Q-amp-A-Eileen-O-Reilly-on-Pancreatic-CancerQ-amp"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":0,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,11,2]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nw2026-0092","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}